Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).

Official Title

A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Keywords

Multiple Myeloma, CC-95266, Relapsed and/or Refractory, Plasma Cell Neoplasms, Cyclophosphamide, Bendamustine Hydrochloride, Fludarabine, Bendamustine, Administration of CC-95266

Eligibility

Locations

  • Local Institution - 012
    San Francisco California 94143 United States
  • Local Institution - 009
    Duarte California 91010-301 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT04674813
Phase
Phase 1 Multiple Myeloma Research Study
Study Type
Interventional
Participants
Expecting 180 study participants
Last Updated